The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring presentations and discussions on genomics, immunity and inflammation, computational approaches for spatial biology, and emerging technologies that are driving the next wave of cancer breakthroughs.
A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus (HPV) protein does not depend on its amino acid sequence or composition.
In a new article published today in Science Translational Medicine, a team of Moffitt Cancer Center researchers, in collaboration with NFlection Therapeutics and researchers at Stanford University, reports the identification of a new drug, NFX-179, that can be applied to the skin and was shown to prevent the development of cutaneous squamous cell carcinoma in pre-clinical models.
Do you know your risk for breast and ovarian cancer? How about steps you can take to reduce your chances of developing cancer or what a family history might mean for your risk of the disease?
Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine (NAM).
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to the understanding of melanoma treatment response and resistance to cancer therapies, including groundbreaking discoveries that reveal how the gut microbiome influences responses to immunotherapy.
In a study co-led by investigators at Dana-Farber Cancer Institute, researchers developed a low-cost, ultrasensitive blood test to detect minute levels of a cancer biomarker that is highly specific to multiple common cancers.
A new study from the UC Davis Violence Prevention Research Program reveals a complex mix of attitudes, concerns and beliefs about the state of democracy and the potential for violence in the United States.
The University of Texas MD Anderson Cancer Center launches a community-wide health care initiative to reduce breast cancer disparities in the Houston area, particularly for Black women. Texas Health Equity Alliance for Breast Cancer (THEAL), seeks to lower the Black/white breast cancer mortality gap in Harris County by 15% over the next decade.
72% of the centers surveyed by NCCN continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.
Alejandro Aballay, Pharm.D., Ph.D., a national leader in immune signaling and graduate education, has been named dean of the MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, effective Jan. 2, 2024.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. October is Breast Cancer Awareness Month.
Robert A. Winn, MD, became president of the Association of American Cancer Institutes (AACI) today at the conclusion of the 2023 AACI/CCAF Annual Meeting in Washington, DC. He succeeds Caryn Lerman, PhD.
Cancer-related fatigue (CRF) is a debilitating yet all-too-common condition, which can severely affect quality of life for patients undergoing treatment. For those struggling with CRF, there have been no effective pharmaceutical treatments for the constellation of symptoms that together define the syndrome.
Investigators from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, investigated genomic alterations based on KRAS status to identify mutations in patients with KRAS wild type (WT).
IDRs comprise a large percentage of the human proteome and are particularly important for nuclear proteins that govern our genomic architecture and gene expression.
Researchers at Dana-Farber Brigham Cancer Center have found that a shorter course of radiation therapy after mastectomy and breast reconstruction surgery provides the same protection against breast cancer recurrence and equivalent physical side-effects but substantially reduces life disruption and financial burden for patients.
Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present new, novel, and expansive radiation oncology data from their clinical research program at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held in San Diego from October 1-4.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, Calif.
What are some of the biggest challenges you face in caring for cancers in children? The biggest challenges are around supporting the parents. For the most part, children are resilient and upbeat.
While researchers continue to make advancements in cancer detection and treatment for breast cancer, one of the best ways to tackle the disease is through early detection and screening with mammography.
What young women should know about breast cancer and screening.
Researchers are working to improve outcomes for Black women with breast cancer – including through increased participation in clinical trials, which helps find better ways to prevent, diagnose and treat cancer.
California’s new Tobacco Cessation Policy Research Center will be located at UC Davis Comprehensive Cancer Center and funded with a $3.7 million state grant
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.
The Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center has received a $10.4 million grant to study the eco-evolutionary dynamics responsible for non-small cell lung cancer growth and treatment resistance.
Evelyn Handel Zapata, PharmD, BCPS, BCOP, Senior Director of Drugs & Biologics Programs at the National Comprehensive Cancer Network® (NCCN®) was named a 40 Under 40 in Cancer: Emerging Leader; launches new resources for a type of pediatric lymphoma.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.
MD Anderson today broke ground on a 600,000-square-foot facility intended to anchor the institution’s expansive south campus research park. The building was purposefully built to enable collaborative science and impactful breakthrough discoveries that will accelerate efforts to end cancer.
In exploring an aspect of how killer T cells generate the raw materials required for their proliferation, a Ludwig Cancer Research study has uncovered an unexpected link between the immune cells’ metabolism, regulation of gene expression, persistence and functional efficacy that could be exploited using existing drugs to improve cancer immunotherapy.
Colon cancers that spread to the liver may be substantially different depending on the location of where cancerous cells originate, according to new research. The study led by Yale Cancer Center researchers at Yale School of Medicine and Yale School of Public Health provides insight into the unique biology of right-sided and left-sided tumors, which may impact treatment options and patient outcomes.
Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.
What advances have made the biggest impact in the treatment of patients with thyroid cancer over the last five years, and what is the outlook for thyroid cancer in the next five years? Molecular testing (MT) to examine somatic changes has become an important adjunct in the diagnosis and treatment of many cancers.
Prostate screening is a critical part of early diagnosis. How would you encourage a man reading this to see his doctor to begin prostate screenings? The decision to screen for prostate cancer is highly individualized, considering each man’s personal risk, race, as well as other potential health conditions.
As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.
The Cancer Research Institute and the Lustgarten Foundation Announce INSPIRE Partnership to Jointly Support Pancreatic Cancer Immunotherapy Research
Moffitt Cancer Center has been awarded a four-year, $3 million grant from the Department of Defense’s Congressionally Directed Medical Research Programs to develop new treatments for rare melanomas, including uveal melanoma. The grant will fund two projects aimed at advancing targeted alpha-particle therapies.
NCCN 2023 Annual Congress: Hematologic Malignancies features expert perspectives on developments in blood cancer treatment, including NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Updates, CAR T-Cell therapy, BTK Inhibitors, Bispecific T-Cell Engagers, and More. The live event is taking place September 22-23, 2023, at the Hilton San Francisco Union Square.
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) today announced a transformative gift from the Commonwealth Foundation for Cancer Research to benefit the Center for Experimental Therapeutics, a multidisciplinary research and drug development group at MSK.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—presented new recommendations for screening and addressing health-related social needs (HRSN) in people with cancer during a policy summit in Washington, D.C.
Fred Hutchinson Cancer Center will serve as the national coordinating center for a new epidemiological cohort study among Asian Americans, Native Hawaiians and Pacific Islanders (AsA-NHPI). Fred Hutch was awarded a seven-year, $38.7 million National Institutes of Health (NIH) grant to coordinate the effort to gather important health information on these populations, which are underrepresented in biomedical research.
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
